Acticor Biotech, a Paris, France-based biotechnology company, completed a €1.4m equity funding.
The funds were raised from investors via the Anaxago crowdfunding platform (€740k), from research association ARMESA (€500k) and from business angels (€170k).
The capital increase will enable the company to continue pre-clinical development and produce initial batches of ACT-017.
Led by Gilles Avenard, CEO, Acticor is developing an anti-thrombotic agent without bleeding risk for the emergency treatment of ischemic strokes. Its ACT-017 inhibits a new target protein, the glycoprotein VI, which is specifically responsible for the growth of blood clots during a stroke.
It is intended to be used alone or in combination with Alteplase®, an emergency treatment which is given to fewer than 10% of patients in the four and a half hours after the first symptoms appearing.